Chapter 34: Antipsychotic Agents and Their Use in Schizophrenia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine your patient suddenly arches their back in the bed.

Like their eyes roll up involuntarily just locked toward the ceiling and their neck twists so sharply it looks like it might actually break.

Right.

And they're struggling to pull air through their vocal cords.

Exactly.

And your first instinct as a nurse on the floor might be that this patient who has a history of severe schizophrenia is having a massive psychotic break or just acting out.

Which is a completely understandable assumption to make in the heat of the moment.

Yeah.

But if you treat it as psychosis and call for like a higher dose of their medication, you could kill them.

You really could.

It's a terrifying scenario, but honestly, it's one of the most critical clinical distinctions you'll ever have to make.

Because what you're actually witnessing in that moment isn't a psychiatric crisis at all.

It's a profound physical drug induced emergency.

And today we're finding out exactly why that happens.

Welcome to this deep dive.

If you're a nursing student studying for your pharmacology exams, or maybe you're just stepping onto the clinical floor for the first time, you are in the exact right place.

We've got a really important mission today.

We do.

Our goal is to decode anti -psychotic agents and their use in schizophrenia.

We're taking all that dense clinical pharmacology and translating it into the cellular why.

Because, I mean, the reasoning behind your medication decisions needs to actually make sense, right?

It can't just be a list you memorize for a test.

Exactly.

So we're going to look really closely at the clinical journey.

We'll examine the two major classes of these medications, the first generation and second generation anti -psychotics, and trace exactly how they alter the brain's chemistry.

And the big takeaway you really need to keep in mind from the jump is this.

Both generations of these drugs treat the symptoms of psychosis equally well.

Yeah.

Neither of them is a cure.

Right.

No cure.

The crucial difference, and honestly, the reason you are tested on this so heavily, is that they have drastically different side effect profiles.

Your entire job when administering these medications is managing those specific trade -offs.

But to manage those trade -offs, we first have to establish what we're actually trying to treat here.

Schizophrenia.

Right.

Schizophrenia is a chronic illness, and it's characterized by episodic acute exacerbations separated by partial remission.

You see disordered thinking and a really reduced ability to comprehend reality.

Biologically speaking, the primary defects in the brain are thought to involve an excessive activation of dopamine receptors alongside an insufficient activation of glutamate receptors.

Right.

And as nursing students, you already know the clinical presentation is typically broken down into positive, negative, and cognitive symptoms.

So we're talking about the addition of hallucinations and delusions that's on the positive side, and then the subtraction of motivation, effect, and speech on the negative side.

But from a pharmacology perspective, I have a question.

Since positive symptoms are basically an overactive behavior and negative symptoms are a deficit, do these drugs target them differently?

Well, it's a very logical question, but clinically the answer is no.

Both the first and second generation drugs respond equally well to both positive and negative symptoms.

Wait, really?

Equal response to both?

Yeah.

The nuance is really in the timeline.

So you'll generally see the positive symptoms like the severe agitation, the delusions, the paranoia, clear up a bit faster than the negative or cognitive symptoms.

Okay.

Those negative symptoms like the blunted affect or social withdrawal, they can take much longer to resolve.

Got it.

Okay, so to understand how we actually suppress those symptoms, we need to go back to, what, the 1950s?

Yeah, the mid -50s.

Right.

Yeah.

This is when the first group of drugs hit the market.

Yeah.

Just completely revolutionized psychiatric care.

The first generation antipsychotics or FGAs.

Also known as conventional antipsychotics or neuroleptics.

The fundamental mechanism of action for FGAs is that they produce a really strong blockade of dopamine 2 or D2 receptors in the mesolimbic area of the brain.

Let's visualize that blockade for a second.

Imagine like a game of musical chairs inside the brain.

Dopamine is just walking around waiting for the music to stop so it can sit in a D2 receptor chair and activate a movement.

I love that analogy.

Thanks.

So FGAs basically rush in and sit in those chairs first.

They're competitive blockers, but they aren't, you know, perfectly precise.

Not at all.

While they're diving for the dopamine chairs, they also accidentally sit in the chairs meant for acetyl choline, histamine, and norepinephrine.

And that collateral blockade is exactly what drives the sci -effect profile, which brings us to a really fascinating classification within FGAs, which is right.

You have low potency agents like chlorpromazine and then high potency agents like haloperidol.

Now potency here doesn't mean one drug is fundamentally stronger or like more effective at treating psychosis than the other.

Which used to confuse me so much in school.

Oh, it confuses everybody.

The maximal clinical effect is identical.

So if they do the exact same thing, why do we care if it's high or low potency?

I always like to think of it like hot sauce.

Okay, let's hear it.

A few drops of ghost pepper hot sauce.

That's your high potency.

Does the exact same job as a whole cup of mild salsa, which is your low potency.

Haloperidol is the ghost pepper.

It needs a tiny dose like two milligrams.

Chlorpromazine is the mild salsa.

It needs a huge dose, maybe a hundred milligrams.

But the end result on the psychosis is identical.

That's spot on.

It comes down to receptor affinity.

A high potency drug like haloperidol binds so tightly to those D2 receptors that you only need that tiny dose to block enough of them.

A low potency drug like chlorpromazine doesn't bind as tightly, so you need a massive dose to achieve that exact same blockade.

And the clinical why here is so important.

Because you're giving such a massive physical dose of the low potency drug,

there are far more molecules floating around the brain spilling over into those other receptor chairs we mentioned.

Precisely.

That is why low potency drugs like chlorpromazine are much more likely to cause sedation from the histamine blockade and orthostatic hypotension from the norepinephrine blockade.

Plus those anti -cholinergic effects like dry mouth from the acetylcholine blockade.

But of course the high potency drugs have their own massive trade -off.

Yeah.

Because haloperidol grabs onto those dopamine chairs so aggressively it accidentally triggers a catastrophic problem in the brain's motor system.

Yes.

The extra -pyramidal symptoms or EPS.

The extra -pyramidal system requires dopamine to coordinate smooth purposeful muscle movements.

So when you aggressively block dopamine with a high potency FGA, you essentially paralyze parts of that motor system.

You do.

And for a nurse, recognizing the timeline of these specific symptoms is critical.

So let's walk through that timeline starting with the scenario we opened the show with.

Acute dystonia.

This happens incredibly fast, right?

Like within the first few hours or days of starting the medication.

Very fast.

The patient develops severe uncontrolled spasms of the muscles of the tongue, face, neck, or back.

You mentioned the eyes rolling up earlier.

That's an oculodgeric crisis.

Oh wow.

Or their back arches severely, which is called opistotonus.

And as we established, you cannot mistake this for psychotic agitation.

It is a physical crisis.

How does a nurse know for sure it's not just a patient acting out or having some kind of psychotic hysteria?

Well, the physical presentation is very distinct and it's dangerous.

Laryngeal dystonia can clamp their airway shut.

They can literally stop breathing.

That is terrifying.

So if I'm the nurse and I recognize this, what is the exact mechanism to fix it?

The immediate intervention is to administer an anti -cholinergic medication like benestropine or even diphenhydramine, either IV or IM.

Just standard benadryl.

Yep.

Because you've blocked so much dopamine, the system is flooded with too much acetylcholine relative to dopamine.

By giving an anti -cholinergic, you restore the balance in the motor system.

And how fast did that work?

The severe spasms usually resolve within five to 20 minutes.

Man, that rapid reversal must feel like an absolute miracle on the floor.

Okay, so moving along the timeline, between five and 30 days of treatment, patients might develop Parkinsonism.

And this looks completely indistinguishable from actual Parkinson's disease, right?

The bradykinesia, the mask -like face drooling, that shuffling gait.

It looks identical because the pathophysiology is identical.

Idiopathic Parkinson's is caused by the death of dopamine -producing neurons in the striatum.

FGA -induced Parkinsonism is caused by the drug -blocking those exact same dopamine receptors.

So you're literally chemically inducing the disease.

Exactly.

But the treatment here is tricky.

Yeah, because if a normal patient has Parkinson's, we give them levodopa to create more dopamine.

Why can't we just give levodopa to these psychiatric patients?

Because it would be a direct chemical tug -of -war.

Levodopa activates dopamine receptors.

If you give it to a patient on an antipsychotic, the levodopa will just completely counteract the antipsychotic drug.

Oh, I see.

You might fix their shuffling gait, sure, but you'll throw them directly back into severe psychosis.

That makes perfect sense.

You can't just undo the drug you just gave, so what do you do?

Instead, you treat it with centrally acting anticholinergics like benstrapine or a drug like amantadine, which help balance the motor pathways without directly overriding the B2 blockade.

Got it.

Okay, next on the timeline happening between, say, five and 60 days is akathisia.

This is that uncontrollable, compulsive need to be in motion, right?

Yes.

The patient is profoundly restless.

They're pacing, squirming, and again, this can so easily be misread as severe anxiety or worsening agitation.

And if you incorrectly up the antipsychotic dose because you think they're agitated?

The akathisia just gets exponentially worse.

To manage it, providers will typically reduce the dosage or maybe switch the patient to a low -potency FGA, which has less aggressive D2 blockade.

Or they might use beta blockers or benzodiazepines to calm the nervous system.

Which brings us to the late reaction.

And honestly, this is the most devastating one.

Tardive dyskinesia or TD.

This develops after months or even years of therapy.

TD is the most troubling extrapure middle symptom because for many patients, it is completely irreversible.

Wait,

the prolonged blockade of dopamine causes the receptors to actually upregulate.

They become super sensitive.

So eventually, even tiny amounts of baseline dopamine cause chaotic, uncontrolled movements.

These were those involuntary choreothoate movements you see in long -term patients, right?

The twisting, writhing, worm -like movements of the tongue and face.

Exactly.

The lip smacking or the tongue flicking out in a fly catching motion.

And over time, I imagine these interfere with just daily life.

Chewing, swallowing, speaking.

Which can lead to severe malnutrition and weight loss.

Because TD is often permanent, prevention is everything in clinical practice.

The goal is always the lowest effective dose for the shortest time possible, and patients require a rigorous neurological evaluation every three months.

Is there any treatment for it once it starts?

It's incredibly difficult.

There are two approved medications, valbenazine and dutrabenazine, but they only manage or reduce the symptoms.

They do not eradicate the underlying damage.

Wow.

So we have this terrifying timeline of motor system side effects.

But outside of that, there is one more rare but incredibly lethal adverse effect of FGAs that can happen at literally any time.

Neuroleptic malignant syndrome or NMS.

Right.

NMS carries a staggering mortality rate if it's not caught immediately.

The hallmark symptoms are this lead pipe muscle rigidity and a sudden high fever that can exceed 41 degrees Celsius.

Which is nearly 106 degrees Fahrenheit.

Plus sweating and severe autonomic instability.

Their blood pressure is fluctuating wildly and they have dangerous cardiac dysrhythmias.

Wait, 106 degrees?

They are biologically boiling.

How does blocking dopamine cause a fever that high?

It's a cascade effect.

The extreme lead pipe muscle contraction generates massive amounts of metabolic heat.

Normally your body would sweat or dilate blood vessels to release that heat, right?

But because the drug has caused autonomic instability, the body's cooling mechanisms just fail.

The heat is trapped.

So if you see that rigidity in that spiked fever, you stop the drug immediately.

That is your very first nursing action.

Then you aggressively manage the hyperthermia with cooling blankets and antipyretics.

And you also have to administer specific rescue drugs.

Right.

You give dantrolene, which is a direct acting muscle relaxant.

This stops the lead pipe rigidity, which stops the generation of metabolic heat.

Exactly.

And you give bromocryptine, which is a dopamine receptor agonist, to overcome the receptor blockade and relieve the central nervous system toxicity.

So because of the sheer severity of these movement disorders and NMS, the pharmaceutical industry basically had to find a better way.

Yeah, they did.

In the 1990s, scientists introduced a new class of drugs that successfully bypassed the extrapyramidal motor system.

But as we're about to see, they kind of traded one massive problem for an entirely different one.

Let's talk about the second generation antipsychotics, or SGA's, using clozapine as our prototype.

The mechanism of action shifts fundamentally with SGA's.

They still block dopamine, but only moderately.

Because the D2 blockade is less aggressive, the risk of all those extrapyramidal symptoms,

the dystonia, the Parkinsonism, the tardive dyskinesia, basically plummets.

Okay, but to make up for that lighter dopamine blockade and still effectively treat the psychosis, SGA's produce a very strong blockade of serotonin receptors, specifically the 5 -HT2 receptors.

Right.

I always found that counterintuitive.

Like if SSRIs increase serotonin to treat depression, why does blocking serotonin help treat schizophrenia?

It's all about specific pathways in the brain.

Blocking 5 -HT2 receptors actually promotes the release of dopamine in certain motor areas of the brain,

which helps offset the extrapyramidal side effects while still maintaining enough blockade in the mesolimbic areas to treat the psychosis.

Clozapine is incredibly effective.

It's often the drug of last resort that works when literally every other antipsychotic has failed.

But there's a massive catch with clozapine.

A rare but potentially fatal reaction called agranulocytosis.

It essentially wipes out the patient's white blood cells, specifically the neutrophils, leaving them completely defenseless against infection.

Yeah.

A simple cold or a minor bacterial exposure can suddenly lead to fatal gram -negative sepsis.

Because of this risk, clozapine is heavily restricted, right?

Health care providers and pharmacies must enroll in a risk evaluation and mitigation strategies program known as REMS.

Absolutely.

As a nurse, you physically cannot administer or dispense this drug without verifying recent normal blood work.

Before they even take their first pill, they must have a normal total white blood cell count of at least 3 ,500 and an absolute neutrophil count or ANC of at least 2 ,000.

And you are monitoring this religiously.

Weekly for the first six months, then every two weeks for the next six months, and then monthly after a year.

And if those numbers drop even slightly below specific thresholds, you have to hold the medication.

And your patient teaching is so vital here.

You have to drill into them that a mild sore throat, a low -grade fever, or just feeling fatigued isn't just a cold, it is a medical emergency.

And they must report it immediately.

Okay.

So agranulocytosis is specific to clozapine.

But when we zoom out and look at the entire class of SGA's drugs like clozapine and olanzapine, we see a much broader systemic issue.

We do.

SGA's essentially trade the motor issues of the FGAs for massive metabolic issues.

We call this the metabolic triad.

And the biological chain of events here is just wild.

It all starts because these drugs block histamine 1 receptors in the brain.

Now, we usually think of histamine for like allergies, but in the central nervous system, histamine regulates arousal and metabolism.

Right.

So when you block it, you lower the patient's resting body temperature, which drastically decreases their daily energy expenditure.

Simultaneously, it triggers insatiable hunger.

Wow.

So they are burning far fewer calories and eating significantly more.

Exactly.

This leads directly to rapid, sometimes massive weight gain.

That sudden increase in adipose tissue creates insulin resistance, paving the way for new onset diabetes.

So patients will suddenly present with classic hyperglycemic symptoms like polyuria, polydipsia, polyphagia.

Yes.

And in extreme cases, it can even progress to diabetic ketoacidosis and coma.

And then to complete the triad, this metabolic dysfunction pairs with dyslipidemia, high total cholesterol, high LDL, high triglycerides, and low HDL.

So the metabolic triad is weight gain, diabetes, and dyslipidemia.

Over time, this dramatically increases the patient's risk of cardiovascular events and premature death.

It really does.

Think about how this changes your nursing assessment.

If your patient is on a first generation drug, you're staring at their face looking for muscle spasms.

But if they're on a second generation drug, you are tracking metabolic markers.

You need baseline and ongoing measurements of their body mass index, their waist circumference, fasting blood glucose, and fasting lipid profiles.

It's a profound shift in clinical focus.

You might even see Metformin added to their daily regimen just to counteract the SGA -induced insulin resistance along with intensive lifestyle and dietary interventions.

But you know, here's the reality of the clinical floor.

Whether a patient is on an FGA and you're worried about movement disorders or an SGA and you're tracking their fasting glucose,

the medication only works if the patient actually swallows it.

Right.

And adherence in schizophrenia is incredibly difficult.

It's a major barrier.

The disease itself can cause patients to fail to appreciate the need for therapy, or they experience these severe side effects we've discussed and simply decide the treatment is worse than the disease.

So if you're administering oral meds, you have to be vigilant.

You have to physically verify they swallow it and aren't cheeking the drug.

Yeah, hiding it in the side of their mouth to spit out in the trash later.

Interestingly, there is one SGA, a centipede, that was designed specifically to combat this.

It comes as a sublingual tablet.

It absorbs directly through the oral mucosa.

If a patient tries to cheek it, the drug just absorbs straight near the cheek tissue anyway.

That's a great workaround.

But a more systemic strategy for adherence involves depo preparations.

These are long acting injectable formulations given deep into the muscle every two to four weeks.

And after injection, the active drug slowly and continuously absorbs into the bloodstream.

Now I have to bring up a common stigma here.

Let's hear it.

I always hear people say that long acting injectables are just a way to physically force non -compliant patients to take their meds against their daily will.

Is that the primary clinical rationale?

No, absolutely not.

That is a really damaging misconception.

Depo preparations are highly valuable for all patients who need long term treatment, regardless of their daily compliance.

Oh, really?

Yeah.

The pharmacokinetics are simply superior.

Think about it.

With daily oral pills,

plasma drug levels peak right after taking it, which causes intense side effects.

And then they drop low right before the next dose, which risks breakthrough psychosis.

Oh, exactly.

Because the drug is absorbed slowly and steadily from the muscle, plasma levels remain flat and constant.

This drastically lowers the relapse rate.

But here is the most important clinical advantage.

Because there are no daily peaks, the total drug burden in the patient's system over a year is actually significantly lower than with oral therapy.

And because the overall drug burden is lower, their risk for developing permanent conditions like tardive dyskinesia is actually reduced.

Yes.

That is a massive clinical benefit.

It is.

Now before we wrap up, there are a few critical safety alerts regarding specific patient populations and nursing handling that you will definitely see on your exams and in practice.

First up is a black box warning that applies equally to both first and second generation antipsychotics.

Neither of these classes should ever be used off label to treat dementia related psychosis in older adults.

It's a vital safety alert.

Administering these drugs to the elderly with dementia literally doubles their rate of mortality.

Doubles it.

Yeah.

The deaths are mostly cardiovascular like sudden heart failure or infectious, specifically pneumonia.

The risks fundamentally outweigh any behavioral control benefits.

Another major lifespan consideration is pregnancy.

If a neonate is exposed to these antipsychotic drugs during the third trimester, they can experience extra pyramidal symptoms or intense withdrawal signs upon birth.

Right.

You might see tremors, severe breathing difficulties, an altered muscle tone in the newborn.

However, the clinical guidance here is nuanced.

Right.

Very.

Despite this risk to the neonate, a pregnant patient should never abruptly discontinue their antipsychotic medication without strict provider guidance.

Because an untreated acute schizophrenic episode during pregnancy carries severe physiological and psychological risks for the mother and the fetus.

Exactly.

It requires very careful medication management.

And finally, a safety warning for you, the nurse actually handling these chemicals.

If you're pouring liquid formulations of phenothiazines, be incredibly careful.

Spilling them on your skin can cause severe contact dermatitis.

Furthermore, certain SGA tablets like risperidone, paliperidone, and zeprasidone, they have the potential to cause reproductive harm or developmental toxicity to healthcare workers who handle them frequently.

Yeah.

The National Institute for Occupational Safety and Health, NOS, their guidelines are very strict on this.

They are.

So if you have to crush or split those specific tablets or handle their liquid forms,

you need to don a protective gown and double glove to prevent microscopic absorption through your skin.

It all comes back to managing the biological environment, both the patient's and your own, with absolute precision and care.

It really does.

So let's step back and look at the massive journey we just took.

We spent the 1950s treating the horrors of psychosis by essentially throwing a heavy, suppressive blanket over the brain's entire motor system with FGAs.

Right.

Then in the 1990s, scientists managed to pull the blanket off the motor system with SGAs, only to accidentally throw it over the dials, controlling human metabolism.

It just highlights how intricate and interconnected the human brain is.

You cannot touch one pathway without cascading into another.

Which leaves you with a really provocative thought to carry into your clinical practice.

If the first generation paralyzed the body and the second generation broke the metabolism,

what entirely new undiscovered receptor combination will the third generation of antipsychotics have to target to finally cure the underlying disease rather than just trading one devastating side effect for another?

It's the ultimate puzzle in psychopharmacology.

And honestly, it's one that the next generation of researchers and the nurses monitoring these patients on the floor are going to have to solve.

And with that, we want to say a huge thank you for joining us on the Deep Dive.

We hope this translated the complexities of antipsychotic pharmacology into something you can actually use.

Good luck on your exams and even more importantly, good luck out there protecting your patients on the floor from the last minute lecture team.

You've got this.